TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06796608

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: Behavioral activation is an evidence-based intervention based on the idea that depression leads to withdrawal from rewarding activities, which sustains or exacerbates depression, and breaks this cycle by increasing the frequency with which people engage in rewarding activities regardless of their motivation. Like those with depression, people living with advanced cancer may reduce or stop participation in meaningful life activities resulting in decreased positive emotion and worse quality of life. The goal of this intervention is to adapt and test a fully remote technology-supported behavioral activation intervention aimed at supporting patients with advanced cancer to optimize the quality of their remaining years of life.
Study: NCT06796023

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching and strengthening exercises for back muscles
Description: Stretching and strengthening exercises for back muscles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching and strengthening exercises for back muscles
Description: Stretching and strengthening exercises for back muscles

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching and strengthening exercises for back muscles
Description: Stretching and strengthening exercises for back muscles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar stabilization Exercises
Description: Lumbar stabilization Exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar Manipulation
Description: Lumbar Manipulation
Study: NCT06793150

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: A comparison will be made by maintaining one group with remifentanil and the other with dexmedetomidine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidin
Description: A comparison will be made by maintaining one group with remifentanil and the other with dexmedetomidine.
Study: NCT06794814

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: oral exercise
Description: The oral exercise protocol included several physical components, namely neck and shoulder stretching, cheek puffing exercises, tongue exercises, salivary gland massage, and oral diadochokinesis.
Study: NCT06795581

Intervention type: DRUG
Group type: OTHER
Intervention: 18F-PF-06445974
Description: Injected IV followed by PET scanning
Study: NCT06795295

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant retained mandibular overdenture
Description: Participants received dental implants to retain mandibular overdentures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant retained mandibular overdenture
Description: Participants received dental implants to retain mandibular overdentures.
Study: NCT06792955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531 injection
Description: Multi-dose pen of HRS9531 injection solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531 injection
Description: Single-dose pen of HRS9531 injection solution.
Study: NCT06796855

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Selective Bladder Denervation via Radiofrequency Ablation
Description: Participants in this arm will undergo a single session of selective bladder denervation using radiofrequency ablation (RFA). The procedure is performed under general anesthesia using the Apro Korea AK-F200 system, which delivers radiofrequency energy at four submucosal points in the bladder trigone area. The energy is applied at 25 watts per site for 60 seconds, targeting nerve pathways involved in overactive bladder symptoms. The procedure is conducted using a 19F rigid cystoscope in lithotomy position, ensuring precise electrode placement. Patients are discharged on postoperative day 1 following urinary ultrasound and post-void residual (PVR) assessment. Follow-up visits are scheduled at 2, 4, and 12 weeks to evaluate symptom improvement and safety.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravesical Onabotulinum Toxin A Injection
Description: Participants in this arm will receive a single dose of 100 units of Onabotulinum Toxin A injected into 10 sites on the bladder wall using a 4mm injection needle and 19F rigid cystoscope. The injection is administered under local anesthesia in an outpatient setting. The Onabotulinum Toxin A is diluted in sterile saline and delivered into the detrusor muscle, aiming to reduce detrusor overactivity and urgency symptoms. Patients undergo urinary ultrasound and post-void residual volume (PVR) assessment on postoperative day 1 before discharge. No additional doses are administered, and follow-up visits are scheduled at 2, 4, and 12 weeks to evaluate symptom improvement and safety.
Study: NCT06791421

Intervention type: OTHER
Intervention: AI-Predictng Model
Description: The intervention in this study involves an AI-based predictive model designed to analyze and integrate patient electronic health records (EHR), clinical lab results, and multimodal imaging data (e.g., X-rays, MRIs, CT scans). The AI model is trained to predict a patient's genotype based on these non-genetic data sources. This model uses machine learning algorithms to detect patterns and infer genetic information that would traditionally require direct genetic testing. There are no active treatments or genetic tests involved in this intervention; rather, the AI system serves as a tool to predict genetic information from available clinical data, offering a non-invasive and potentially more accessible alternative to genetic testing.
Study: NCT06796543

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Consolidative radiation therapy (cRT)
Description: Treatment that is given after cancer has disappeared following the initial therapy. Consolidation therapy is used to kill any cancer cells that may be left in the body. It may include radiation therapy, a stem cell transplant, or treatment with drugs that kill cancer cells. Also called intensification therapy and postremission therapy.
Study: NCT06794164

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin to skin care
Description: skin to skin care of preterm infants with their parents immediately after birth
Study: NCT04692649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pragmatic posterior capsular stretch
Description: pragmatic posterior stretch is used to increase the length of the posterior capsule

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cross body stretch
Description: crossbody stretch performed by an individual
Study: NCT05705765

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Instability training
Description: Training on unstable surfaces. 12 sessions of 40-45 min in four weeks.
Study: NCT06427590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC47
Description: single subcutaneous injection of ASC47

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC47
Description: single subcutaneous injection of ASC47

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC47
Description: single subcutaneous injection of ASC47

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC47
Description: single subcutaneous injection of ASC47
Study: NCT05229003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib 8mg or 10mg, d1-9，q2w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib 8mg or 10mg, d1-9，q2w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab
Description: Penpulimab 200mg, d6, q2w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 180mg/m2, d6, q2w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 180mg/m2, d6, q2w
Study: NCT04627987

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI scan
Description: Cardiac MRI scan pre- and post- aortic valve replacement to assess degree of left ventricular remodelling, fibrosis and myocardial blood flow.

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum biomarkers (High sensitivity troponin, NT-proBNP
Description: Blood tests looking evidence of cardiac structural remodelling and function.

Intervention type: PROCEDURE
Intervention: Implantable Loop Recorder
Description: Determine post-AVR arrhythmia burden

Intervention type: DIAGNOSTIC_TEST
Intervention: 6 minute walk test
Description: Validated assessment of functional capacity - distance walked over 6 minute time frame.

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogram
Description: Ultrasound assessment of heart structure and function. Standard of care in valve surgery pathway.
Study: NCT05239624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin
Description: Enfortumab vedotin will be administered at 1.25 mg/kg on day 1 and day 8 of each 21-day cycle, for up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered on day 1 of each cycle, every 21 days, for 6 cycles.
Study: NCT05275920

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice Alert (BPA)
Description: A BPA will fire in the EHR reminding care providers of the best practice when prescribing medical therapies for heart failure patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In-Basket Message
Description: An In-Basket message will be sent biweekly to care providers with a reminder of the best practice when prescribing medical therapies for heart failure
Study: NCT05437588

Intervention type: GENETIC
Group type: OTHER
Intervention: Genetic testing
Description: Attempting to identify the genetic biomarker that can identify risk for suicidal ideation and action
Study: NCT04899544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Center-Based Pivotal Response Treatment (PRT) Intervention (PRT-C)
Description: Pivotal Response Treatment in autism center.
Study: NCT06427590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC47
Description: single subcutaneous injection of ASC47

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: single subcutaneous injection of Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: single subcutaneous injection of Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: single subcutaneous injection of Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: single subcutaneous injection of Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: single subcutaneous injection of Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: single subcutaneous injection of Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: single subcutaneous injection of Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: single subcutaneous injection of Placebo
Study: NCT05577260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isobaric bupivacaine
Description: 20ml isobaric bupivacaine 0.25%
Study: NCT06110468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CoreDISTParticipation
Description: CoreDISTparticipation is a multi-disciplinary individualized intervention that concurrently combine 1) providing PwMS and their employers with information on MS, possibilities for work-adaptations within the welfare system and the importance of physical activity 2) Structured goal-setting regarding reducing barriers for work and regarding physical function and activity for PwMS 3) A physiotherapy intervention focusing on improving the underlying prerequisites for balance and walking along with high intensive training and promotion of physical activity 4) structured evaluation and adjustment of goals.
Study: NCT03960099

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pictograph in Banner and Verification Alert
Description: Patient Pictograph will be displayed in the banner at the top of the screen in the electronic health record AND patient Pictograph displayed in a patient ID verification alert when placing electronic orders in the electronic health record.
Study: NCT05874414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNS561 + Trametinib
Description: GNS561: 50mg, 100mg, 150mg, 200mg and trametinib: 1mg, 1.5mg and 2mg
Study: NCT06533865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Six monthly subcutaneous injections. This group will also receive a 100-microgram transdermal estradiol patch applied twice weekly, and 200 mg of oral progesterone for the first 12 days of each month.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical to romosozumab but inactive. This group will also receive a 100-microgram transdermal estradiol patch applied twice weekly, and 200 mg of oral progesterone for the first 12 days of each month.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zoledronic acid
Description: One intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: One intravenous infusion
Study: NCT05115864

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PFMT with device
Description: The wearable PFMT device (XFT-0010CK) is made by two parts. One part is the screen device which is able to show the real-time vaginal resting pressure and voluntary contraction pressure in units of mmHg. The other part is a vaginal air-filled probe. The two parts are combined with a thin air tube. The whole device is connected to a smartphone app by Bluetooth to record the progress of PFMT. There are two modes of the device, one is assessment mode, when it comes to the assessment mode that the device is able to assess the grade of type I and II pelvic floor muscle fiber strength by the patients themselves, the other mode is practice mode by displaying real-time visual pressure value according to the completeness of the PFMT program.
Study: NCT06260631

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-intensity laser acupuncture and Exercise therapy program
Description: The experimental group will receive high-intensity lasers and the treatment will be performed at 15 acupuncture points: unilateral GV3, GV4, and GV5, and bilateral BL 20, BL23, BL24, BL25, BL40 and GB30.~Exercise therapy program~The patients will perform an exercise therapy program in the form of:~* strengthening exercises for abdominal and back muscles,~* lumbar stabilization exercises.~* stretching exercises.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham laser acupuncture
Description: Sham laser acupuncture and exercise therapy program~The patients will receive a sham laser.acupuncture and an exercise therapy program in the form of:~* strengthening exercises for abdominal and back muscles,~* lumbar stabilization exercises.~* stretching exercises.
Study: NCT06152042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMF-219
Description: BMF-219 is an orally bioavailable, covalent small-molecule menin inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMF-219
Description: BMF-219 is an orally bioavailable, covalent small-molecule menin inhibitor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BMF-219
Description: BMF-219 is an orally bioavailable, covalent small-molecule menin inhibitor.
Study: NCT06514794

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WU-CART-007
Description: A single IV infusion of WU-CART-007 cells on Day 1
Study: NCT04810546

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Jarrow Formulas Oral Bovine Lactoferrin Supplement
Description: Lactoferrin (Apolactoferrin) 250mg contains \~17.6 mg/100g of iron
Study: NCT04844879

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NextAR TKA system
Description: The NextAR TKA system is a surgical guidance system which measures intra-operatively the effect of prosthesis alignment and positioning on soft tissue balance.
Study: NCT06019000

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: CYR-064
Description: CYR-064 is a nasal solution.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CYR-064
Description: CYR-064 is a nasal solution.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: CYR-064
Description: CYR-064 is a nasal solution.
Study: NCT05517655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 129Xe
Description: Rapid spatial mapping of lung, liver, and pancreatic structure and function is now possible with a combination of hyperpolarized 129Xe and traditional proton MRI, all absent sedation and ionizing radiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 129Xe
Description: Rapid spatial mapping of lung, liver, and pancreatic structure and function is now possible with a combination of hyperpolarized 129Xe and traditional proton MRI, all absent sedation and ionizing radiation.
Study: NCT06192433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-frequency repetitive transcranial magnetic stimulation (40Hz)
Description: Participants in this group receive high-frequency TMS at 40 Hz. The TMS intervention is applied to the bilateral dorsolateral prefrontal cortex (DLPFC). Each patient undergoes this TMS treatment for a course of 10 consecutive working days. The specific parameters for TMS include pulses at 40 Hz with an intensity set at 40% of the maximum intensity. Each pulse lasts for 2 seconds, followed by a 58-second rest period. On each treatment day, patients receive 30 sets of stimulation, with 15 stimulations applied to the left side and 15 to the right side, totaling 2400 pulses.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Moderately high-frequency repetitive transcranial magnetic stimulation (10Hz)
Description: Participants in this group receive moderately high-frequency TMS at 10 Hz. Similar to the high-frequency group, the TMS intervention targets the bilateral dorsolateral prefrontal cortex (DLPFC) and is administered for a course of 10 consecutive working days. The TMS parameters for this group involve pulses at 10 Hz with an intensity set at 90% of the maximum intensity. Each pulse lasts for 4 seconds, followed by a 56-second rest period. As in the high-frequency group, patients in this group also receive 30 sets of stimulation per treatment day, with 15 stimulations applied to the left side and 15 to the right side, totaling 2400 pulses.
Study: NCT05929833

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BETTER (Brain Injury, Education, Training, and Therapy to Enhance Recovery)
Description: The six components of BETTER include: 1) assessment of patient/family needs and referral to community-based resources; 2) patient goal setting and review of goals; 3) health care coordination; 4) availability of clinical interventionist to patient/family; 5) training on self- and family-management and brain injury coping skills; and 6) warm hand off/referral to the state-affiliated Brain Injury Association at the end of the intervention for additional resources.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Usual care discharge planning process and follow up (e.g., verbal and written discharge instructions, with guidance on medications, outpatient therapy, and follow-up appointments)
Study: NCT06343818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Compassion Project: Intervention to Reduce Empathy-Based Stress in Staff
Description: Six month package of training and resources delivered to ward staff, including bite-sized audio, video and written materials. Face to face training will be provided weekly by a clinical psychologist. A staff group of 'compassion champions' will be responsible for embedding the intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Compassion Project: Intervention to Reduce Empathy-Based Stress in Staff
Description: Six month package of training and resources delivered to ward staff, including bite-sized audio, video and written materials. Face to face training will be provided weekly by a clinical psychologist. A staff group of 'compassion champions' will be responsible for embedding the intervention.
Study: NCT05024916

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention
Description: 26 g packets of freeze-dried blueberries (equivalent to 1 cup of fresh blueberries) will be given to participants to be consumed daily. Participants will be asked to consume 1 packet per day for 3 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: 26 g packets of isocaloric carbohydrate-matched powder will be given to participants to be consumed daily. Participants will be asked to consume 1 packet/day for 3 months.
Study: NCT03784131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P-TEV
Description: Replacement of vein with failing valves with personalized tissue engineering vein containing functional valves
Study: NCT05678816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BREATHER
Description: respiratory muscle trainer used to strength inspiratory an expiratory muscles through breathing in and out against aresistence which is determined individually according to each patient.
Study: NCT05532592

Intervention type: OTHER
Intervention: Perceptions and attitudes towards COVID-19 and COVID-19 vaccine
Description: Attitude towards COVID-19; Knowledge about COVID-19 vaccine

Intervention type: OTHER
Intervention: Perceptions and attitudes towards COVID-19 and COVID-19 vaccine
Description: Attitude towards COVID-19; Knowledge about COVID-19 vaccine
Study: NCT06794164

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care (in control arm)
Description: skin to skin care within 24 hours after birth
Study: NCT04571970

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RGX-121
Description: Recombinant adeno-associated virus serotype 9 capsid containing human iduronate-2-sulfatase expression cassette
Study: NCT06797570

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Strategy for Side Effect Counseling in ADHD Treatment
Description: One group receives negatively framed and extensive information about the most common adverse events of methylphenidate. A fixed script will be prepared for the treating paediatrician, and the same information will be provided in written form. The other group receives positively framed and concise information about the most common adverse events of methylphenidate. This information will also be provided in written form.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Strategy for Side Effect Counseling in ADHD Treatment
Description: One group receives negatively framed and extensive information about the most common adverse events of methylphenidate. A fixed script will be prepared for the treating paediatrician, and the same information will be provided in written form. The other group receives positively framed and concise information about the most common adverse events of methylphenidate. This information will also be provided in written form.